These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 7985892)

  • 1. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
    Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
    N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
    Fischl MA; Olson RM; Follansbee SE; Lalezari JP; Henry DH; Frame PT; Remick SC; Salgo MP; Lin AH; Nauss-Karol C; Lieberman J; Soo W
    Ann Intern Med; 1993 May; 118(10):762-9. PubMed ID: 8097082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
    N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
    Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
    J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
    N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
    Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
    Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
    J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.